Augmentation strategies in electroconvulsive therapy

Journal of ECT

Volumn 26, Issue 3, 2010, Pages 202-207

  Loo, Colleen ^a,b,c   Simpson, Brett ^a,c   MacPherson, Ross ^d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c ST GEORGE HOSPITAL   (Australia)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

caffeine; electroconvulsive therapy; hyperventilation; ketamine remifentanil

Indexed keywords

AMINOPHYLLINE; BARBITURIC ACID DERIVATIVE; CAFFEINE; KETAMINE; REMIFENTANIL; THEOPHYLLINE; XANTHINE DERIVATIVE;

DRUG MECHANISM; ELECTROCONVULSIVE THERAPY; HUMAN; HYPERVENTILATION; REVIEW; SEIZURE; TREATMENT OUTCOME;

CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; COMBINED MODALITY THERAPY; ELECTROCONVULSIVE THERAPY; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; HYPERVENTILATION; HYPNOTICS AND SEDATIVES; KETAMINE; PIPERIDINES; TREATMENT OUTCOME;

EID: 77956463631     PISSN: 10950680     EISSN: 15334112     Source Type: Journal    
DOI: 10.1097/YCT.0b013e3181e48143     Document Type: Review

References (76)

1. Schwartz CM. Electroconvulsive and Neuromodulation Therapies. New York, NY: Cambridge University Press; 2009.
2. Mukherjee S, Sackeim HA, Schnur DB. Electroconvulsive therapy of acute manic episodes: a reviewof 50 years' experience. Am J Psychiatry. 1994;151:169Y176.
3. Sackeim HA, Prudic J, Nobler MS, et al. Effects of pulse width and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. Brain Stimulat. 2008;1:71Y83.
4. Loo C, Sainsbury K, Sheehan P, et al. A comparison of RUL ultra-brief pulse ECT and standard RUL ECT. Int J Neuropsychopharmacol. 2008;11:883Y890.
5. Bergsholm P, Gran L, Bleie H. Seizure duration in unilateral electroconvulsive therapy. The effect of hypocapnia induced by hyperventilation and the effect of ventilation with oxygen. Acta Psychiatr Scand. 1984;69:121Y128.
6. Chater SN, Simpson KH. Effect of passive hyperventilation on seizure duration in patients undergoing electroconvulsive therapy. Br J Anaesth. 1988;60:70Y73.
7. Holmberg G. The factor of hypoxemia in electroshock therapy. Am J Psychiatry. 1953;110:115Y118.
8. Rasanen J, Martin DJ, Downs JB, et al. Oxygen supplementation during electroconvulsive therapy. Br J Anaesth. 1988;61:593Y597.
9. Pande AC, Shea J, Shettar S, et al. Effect of hyperventilation on seizure length during electroconvulsive therapy. Biol Psychiatry. 1990;27: 799Y801.
10. Sawayama E, Takahashi M, Inoue A, et al. Moderate hyperventilation prolongs electroencephalogram seizure duration of the first electroconvulsive therapy. J ECT. 2008;24:195Y198.
11. Mayur P, Bray A, Fernandes J, et al. Impact of hyperventilation in optimizing ECT stimulus during the early phase of electroconvulsive therapy. A randomised double-blind study. 19th Annual Meeting of Association for Convulsive Therapy. San Francisco, CA; 2009.
12. Sackeim HA, Prudic J, Devanand DP, et al. Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. N Engl J Med. 1993;328:839Y846.
13. Krystal AD, Weiner RD, McCall WV, et al. The effects of ECT stimulus dose and electrode placement on the ictal electroencephalograph: an intraindividual crossover study. Biol Psychiatry. 1993;34: 759Y767.
14. Nobler MS, Sackeim HA, Solomou M, et al. EEG manifestations during ECT: effects of electrode placement and stimulus intensity. Biol Psychiatry. 1993;34:321Y330.
15. American Psychiatric Association, Committee on Electroconvulsive Therapy. The Practice of Electroconvulsive Therapy: recommendationsfor treatment, training, and privileging: a task force report of the American Psychiatric Association. 2nd Ed. Washington, DC: American Psychiatric Association; 2001.
16. Fisone G, Borgkvist A, Usiello A. Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004;61:857Y872.
17. Coffey CE, Weiner RD, Hinkle PE, et al. Augmentation of ECT seizures with caffeine. Biol Psychiatry. 1987;22:637Y649.
18. Hinkle PE, Coffey CE, Weiner RD, et al. Use of caffeine to lengthen seizures in ECT. Am J Psychiatry. 1987;144:1143Y1148.
19. Shapira B, Lerer B, Gilboa D, et al. Facilitation of ECT by caffeine pretreatment. Am J Psychiatry. 1987;144:1199Y1202.
20. Coffey CE, Figiel GS, Weiner RD, et al. Caffeine augmentation of ECT. Am J Psychiatry. 1990;147:579Y585.
21. Calev A, Fink M, Petrides G, et al. Caffeine pretreatment enhances clinical efficacy and reduces cognitive effects of electroconvulsive therapy. Convuls Ther. 1993;9:95Y100.
22. McCall WV, Reid S, Rosenquist P, et al. A reappraisal of the role of caffeine in ECT. Am J Psychiatry. 1993;150:1543Y1545.
23. Kelsey MC, Grossberg GT. Safety and efficacy of caffeine-augmented ECT in elderly depressives: a retrospective study. J Geriatr Psychiatry Neurol. 1995;8:168Y172.
24. Rosenquist PB, McCall WV, Farah A, et al. Effects of caffeine pretreatment on measures of seizure impact. Convuls Ther. 1994;10:181Y185.
25. Lurie SN, Coffey CE. Caffeine-modified electroconvulsive therapy in depressed patients with medical illness. J Clin Psychiatry. 1990;51: 154Y157.
26. Ancill RJ, Carlyle W. Oral caffeine augmentation of ECT. Am J Psychiatry. 1992;149:137.
27. Jaffe R, Brubaker G, Dubin WR, et al. Caffeine-associated cardiac dysrhythmia during ECT: report of three cases. Convuls Ther. 1990;6:308Y313.
28. Acevedo AG, Smith JK. Adverse reaction to use of caffeine in ECT. Am J Psychiatry. 1988;145:529Y530.
29. Beale MD, Pritchett JT, Kellner CH. Supraventricular tachycardia in a patient receiving ECT, clozapine, and caffeine. Convuls Ther. 1994;10:228Y231.
30. Cua WL, Pease Campbell JA, Stewart JT. A case of ventricular tachycardia related to caffeine pretreatment. J ECT. 2009;25:70Y71.
31. Enns M, Peeling J, Sutherland GR. Hippocampal neurons are damaged by caffeine-augmented electroshock seizures. Biol Psychiatry. 1996; 40:642Y647.
32. Swartz CM, Lewis RK. Theophylline reversal of electroconvulsive therapy (ECT) seizure inhibition. Psychosomatics. 1991;32:47Y51.
33. Stewart JT. Prolongation of ECT-induced seizures with theophylline. J Am Geriatr Soc. 1996;44:475.
34. Leentjens AF, van den Broek WW, Kusuma A, et al. Facilitation of ECT by intravenous administration of theophylline. Convuls Ther. 1996;12:232Y237.
35. Bahls FH, Ma KK, Bird TD. Theophylline-associated seizures with Btherapeutic[ or low toxic serum concentrations: risk factors for serious outcome in adults. Neurology. 1991;41:1309Y1312.
36. Peters SG, Wochos DN, Peterson GC. Status epilepticus as a complication of concurrent electroconvulsive and theophylline therapy. Mayo Clin Proc. 1984;59:568Y570.
37. Devanand DP, Decina P, Sackeim HA, et al. Status epilepticus following ECT in a patient receiving theophylline. J Clin Psychopharmacol. 1988;8:153.
38. Crider BA, Hansen-Grant S. Nonconvulsive status epilepticus as a cause for delayed emergence after electroconvulsive therapy. Anesthesiology. 1995;82:591Y593.
39. Rasmussen KG, Zorumski CF. Electroconvulsive therapy in patients taking theophylline. J Clin Psychiatry. 1993;54:427Y431.
40. Stern L, Dannon PN, Hirschmann S, et al. Aminophylline increases seizure length during electroconvulsive therapy. J ECT. 1999;15: 252Y257.
41. Katagai H, Yasui-Furukori N, Kikuchi A, et al. Bemegride lengthens seizure duration during electric convulsive therapy in a schizophrenic patient with increased seizure threshold. J ECT. 2009;25:61Y63.
42. Scott AIF. Psychotropic drug treatment during and after ECT. The ECT HandbookVThe Third Report of the Royal College of Psychiatrists' Special Committee on ECT. London, UK: The Royal College of Psychiatrists; 2005.
43. Porter R, Booth D, Gray H, et al. Effects of the addition of remifentanil to propofol anesthesia on siezure length and postictal suppression index in electroconvulsive therapy. J ECT. 2008;24:203Y207.
44. Rasmussen KG, Imig MW, Varghese R. Remifentanil/thiopental combination and seizure length in electroconvulsive therapy. J ECT. 2009;25:31Y33.
45. Nasseri K, Arasteh NT, Maroufi A, et al. Effects of remifentanil on convulsion duration and hemodynamic responses during electroconvulsive therapy: a double-blind, randomized clinical trial. J ECT. 2009;25:170Y173.
46. Sullivan PM, Sinz EH, Gunel E, et al. A retrospective comparison of remifentanil versus methohexital for anesthesia in electroconvulsive therapy. J ECT. 2004;20:219Y224.
47. Sienaert P, Bouckaert F, Hagon A, et al. Short seizures in continuation electroconvulsive therapy: an indication for remifentanil anesthesia? J ECT. 2004;20:130Y131.
48. Augoustides JG, Hosalkar HH, O'Reardon JP, et al. Customized anesthetic preparation of ictal threshold in electroconvulsive therapy: role of adjunctive remifentanil with etomidate. J ECT. 2005;21:128Y131.
49. Loo C, Sainsbury K, Martin D, et al. Synergistic antidepressant effects with ketamine and ECT. J ECT. 2009;25:150.
50. Lalla FR, Milroy T. The current status of seizure duration in the practice of electroconvulsive therapy. Can J Psychiatry. 1996;41:299Y304.
51. Kraepelin E. Einfu'hrung in Die Psychiatrische Klinik: Zweiunddreissig Vorlesungen. Leipzig, Germany: K. A. Barth; 1905. Cited by: Tenore P. Psychotherapeutic benefits of opioid agonist therapy. J Addict Dis. 2008;27:49Y65.
52. Kennedy SE, Koeppe RA, Young EA, et al. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry. 2006;63:1199Y1208.
53. Tenore PL. Psychotherapeutic benefits of opioid agonist therapy. J Addict Dis. 2008;27:49Y65.
54. Extein I, Pickar D, Gold MS, et al. Methadone and morphine in depression. Psychopharmacol Bull. 1981;17:29Y33.
55. Emrich H, Vogt P, Herz A. Possible antidepressant effects of opioids: actions of buprenorphine. Ann N Y Acad Sci. 1982;398:108Y112.
56. Nyhuis PW, Gastpar M, Scherbaum N. Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy. J Clin Psychopharmacol. 2008;28:593Y595.
57. Berrocoso E, Sanchez-Blazquez P, Garzon J, et al. Opiates as antidepressants. Curr Pharm Des. 2009;15:1612Y1622.
58. Macpherson R, Loo C. Cognitive impairment following ECTVdoes the choice of anaesthetic agent make a difference? J ECT. 2008; 24:52Y56.
59. Zacny J. A reviewof the effects of opioids on cognitive and psychomotor functioning in humans. Exp Clin Psychopharmacol. 1995;3:432Y466.
60. Carrasco M, Dias R, Izquierdo I. Naloxone reverses retrograde amnesia induced by electroconvulsive shock. Behav Neural Biol. 1982;34: 352Y357.
61. Prudic J, Fitzsimons L, Nobler M, et al. Naloxone in the prevention of the adverse cognitive effects of ECT: a within-subject, placebo controlled study. Neuropsychopharmacology. 1999;21:285Y293.
62. Faden A. Neurotoxic versus neuroprotective actions of endogenous opioid peptides: implications for treatment of CNS injury. NIDA Res Monogr. 1996;163:318Y330.
63. Fodale V, Schifilliti D, Pratico C, et al. Remifentanil and the brain. Acta Anaesthesiol Scand. 2008;52:319Y326.
64. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351Y354.
65. Zarate CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856Y864.
66. Liebrenz M, Borgeat A, Leisinger R, et al. Intravenous ketamine therapy in a patient with treatment-resistant major depression. Swiss Med Wkly. 2007;137:234Y236.
67. Paul R, Schaaff N, Padberg F, et al. Comparison of racemic ketamine and S-ketamine in treatment resistant major depression: report of two cases. World J Biol Psychiatry. 2009;10:241Y244.
68. Maeng S, Zarate C, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of amino-3-hydroxy-5-methylisoxazole-4- propionic acid receptors. Biol Psychiatry. 2008;63:349Y352.
69. Krystal AD, Weiner RD, Dean MD, et al. Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT. J Neuropsychiatry Clin Neurosci. 2003;15:27Y34.
70. Ostroff R, Gonzales M, Sanacora G. Antidepressant effects of ketamine during ECT. Am J Psychiatry. 2005;162:1385Y1386.
71. Goforth HW, Holsinger T. Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy. J ECT. 2007;23:23Y25.
72. Ding Z, White PF. Anesthesia for electroconvulsive therapy. Anesth Analg. 2002;94:1351Y1361.
73. Rasmussen KG, Jarvis MR, Zorumski CF. Ketamine anesthesia in electroconvulsive therapy. Convuls Ther. 1996;12:217Y223.
74. White PF, Way WL, Trevor AJ. KetamineVits pharmacology and therapeutic uses. Anesthesiology. 1982;56:119Y136.
75. McDaniel WW, Sahota AK, Vyas BV, et al. Ketamine appears associated with better word recall then etomidate after a course of 6 electroconvulsive therapies. J ECT. 2006;22:103Y106.
76. Morgan CJ, Curran HV. Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology. 2006;188:408Y424.